The Nelkarmi FDA approval came on 17 November 2026, when the US Food and Drug Administration granted accelerated approval to GSK’s neladalkib for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) whose disease was previously treated with alectinib, or with two or more ALK inhibitors plus platinum chemotherapy. The decision arrived 10 days ahead of the 27 November target date and rests on response data from the ALKOVE-1 trial, in which 49% of post-alectinib patients saw their tumours shrink, according to GSK’s announcement.
Key takeaways on the Nelkarmi FDA approval
- Nelkarmi (neladalkib) is a once-daily 150 mg oral ALK inhibitor, now approved in the US for two pretreated ALK-positive NSCLC groups.
- Confirmed response rate: 49% after alectinib alone (n=67) and 32% after two or more ALK inhibitors plus chemotherapy (n=155).
- In patients with measurable brain metastases, intracranial response reached 55% and 26% in the same two groups.
- Liver toxicity is the main safety issue: 56% of patients in the pooled safety set had hepatotoxicity, 18% grade 3 and 7% grade 4.
- It is GSK’s second lung cancer approval of 2026 and the second drug from its Nuvalent acquisition, after Jideytro (zidesamtinib) for ROS1-positive NSCLC in July.
Who the approval covers
ALK rearrangements drive a small share of NSCLC, often in younger people who never smoked. First-line treatment usually means a powerful ALK inhibitor such as alectinib or lorlatinib, and many patients live for years on these drugs. When the cancer eventually adapts, often through resistance mutations such as G1202R or by spreading to the brain, options narrow quickly to chemotherapy. Nelkarmi was designed to stay active against those resistance mutations while penetrating the central nervous system, and to avoid TRK inhibition, which is linked to some of the neurological side effects seen with lorlatinib.
ALKOVE-1 results behind the decision
ALKOVE-1 is a single-arm, global Phase 1/2 study that enrolled about 700 patients with ALK-positive tumours. The efficacy analysis for this approval included 222 previously treated NSCLC patients, with tumour response confirmed by blinded independent central review.
| Measure | After alectinib only | After 2+ ALK TKIs and chemotherapy |
|---|---|---|
| Patients | 67 | 155 |
| Confirmed ORR (95% CI) | 49% (37-62%) | 32% (24-40%) |
| Responders lasting 6+ months | 76% | 69% |
| Responders lasting 12+ months | 52% | 51% |
| Intracranial ORR (measurable brain metastases) | 55% (11/20) | 26% (14/53) |
| Intracranial complete response | 25% | 11% |
The pattern is clear: the drug works best earlier in the resistance journey. Data presented at ASCO 2026 told the same story, with a 46% response rate in lorlatinib-naive patients against 26% in those already given lorlatinib, and median progression-free survival of 14.5 months versus 4.6 months, as OncLive summarised. That is why the label is split into two groups rather than covering all pretreated patients.
Safety: liver monitoring is the price of entry
Across 700 treated patients, the most common side effects were liver enzyme rises (56%), musculoskeletal pain (33%), constipation (28%), altered taste (24%), peripheral neuropathy (23%), swelling (21%) and fatigue (21%). Severe drug-induced liver injury and liver failure were rare at 0.3% and 0.4%, and only 3% stopped treatment because of liver effects. The label tells doctors to check liver tests at baseline, every two weeks for the first two months, then monthly.
Other warnings cover eye problems (14%, including retinal detachment and corneal erosion), creatine kinase elevation (28%), rare acute kidney injury and harm to a developing baby. Serious adverse reactions occurred in 30% of patients and fatal ones in 1.1%. Strong or moderate CYP3A inhibitors and inducers should be avoided. Treatment decisions belong with the patient’s oncologist.
What accelerated approval means here
Accelerated approval is based on tumour response and how long it lasts, not on proof that patients live longer. Continued approval may depend on a confirmatory trial. The key study is ALKAZAR, a Phase 3 trial comparing neladalkib with alectinib in patients who have never had an ALK inhibitor, with closer liver monitoring built in. If it succeeds, Nelkarmi could move into first-line treatment, which is where most of the commercial and clinical value lies.
Market context and the GSK deal
Reuters described Nelkarmi as GSK’s second lung cancer drug from its $10.6 billion purchase of Nuvalent. GSK chief scientific officer Tony Wood called it “our second new medicine approved in lung cancer this year.” Two approvals within five months give GSK a precision lung cancer franchise it lacked a year ago.
For a sense of scale, Acumen Research and Consulting estimated the global lung cancer market at $21.1 billion in 2021 and projected it to reach $67.9 billion by 2030, growing at 14.1% a year, with Asia-Pacific the fastest-growing region. Those figures date from a February 2023 update and should be read as indicative, but they show why targeted drugs for small genetic subgroups like ALK attract multibillion-dollar deals.
For patients in India and other Asian markets, where ALK testing is increasingly routine, the approval is US-only for now. GSK’s release does not mention filings in other countries, so availability elsewhere depends on future submissions to regulators such as CDSCO. Readers following lung cancer research may also want our report on Roche’s divarasib Phase 3 results.
FAQ
What is Nelkarmi (neladalkib) used for?
It treats adults with locally advanced or metastatic ALK-positive NSCLC that has progressed after alectinib, or after two or more ALK inhibitors and platinum chemotherapy.
How effective is neladalkib?
In ALKOVE-1, 49% of post-alectinib patients and 32% of more heavily pretreated patients had confirmed tumour shrinkage, with about half of responders still responding at 12 months.
Does Nelkarmi work on brain metastases?
Yes, in the trial. Intracranial response rates were 55% after alectinib and 26% in the more pretreated group among patients with measurable brain lesions.
Is Nelkarmi available in India?
Not at present. The approval is from the US FDA, and GSK has not announced an Indian filing.
More approvals: FDA Approvals.
Sources: GSK press release; OncLive; Reuters. Market data: Acumen Research and Consulting, Lung Cancer Market report (2023 update, indicative). Not medical or investment advice. Last updated 18 November 2026.
